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Abstract
The inflammatory and immunologic processes responsible for asthma can produce permanently fixed
obstructive lung disease unresponsive to medical therapy. This can be manifested clinically by the
failure of a childhood asthmatic to reach full expected lung capacity at adulthood and by an
accelerated decline in pulmonary capacity in adults. Recent studies have furthered our insight into the
pathologic processes underlying these changes and the potential effects of therapy to prevent them.
Introduction and context
Twenty years ago, asthma was universally thought of as a
reversible, obstructive pulmonary disease. It was not
until the 1990s that the concept that asthma could
produce irreversible obstructive changes was introduced
[1]. A search of the medical literature revealed only two
references to pulmonary remodeling in asthma between
1990 and 2000. Today, a similar search reveals 1477
references. The structural changes that produce this
irreversibility are damage to the epithelium, smooth
muscle hyperplasia and hypertrophy, the deposition of
glycoproteins in the parenchyma, the destruction of
elastin, neovascularization, a thickened sub-basement
membrane, and mucous gland hyperplasia [2].
It has now become clear that a significant number of
asthmatics are at risk for development of these perma-
nent changes, and that the degree of impairment
produced by the remodeling process is clinically
significant [3-5]. As many as 25% of childhood
asthmatics are at risk for impaired lung growth [4] and
as many as 16% of adult asthmatics exhibit a permanent
and accelerated decline in lung function [5]. These
changes can amount to a reduction of a liter or more in
forced expiratory volume in one second (FEV1) [6,7].
The underlying forces that drive the remodeling process
consist of a panoply of inflammatory mediators that
have destructive, restorative, and chemotactic properties
and include, amongst many others, transforming growth
factor beta, the metalloproteinases, eotaxin and other
eosinophilic chemotactic agents, tryptase, histamine,
elastase, and various interleukins (including IL-4, IL-5,
IL-6, IL-9, and IL-13) [8-13]. The histologic changes
characteristic of remodeling include smooth muscle
hyperplasia, deposition of collagen and glycoproteins
beneath the sub-basement membrane, goblet cell hyper-
plasia, airway epithelial cell proliferation and destruc-
tion, deposition of glycoproteins in the pulmonary
parenchyma, and neovascularization.
Over the past several years, a number of risk factors have
been identified that make it more likely that, in any given
individual asthmatic, the remodeling process will occur
[14,15]. These risk factors are listed in Table 1.
Finally, it should be made very clear that the process of
remodeling in asthma is distinct from the pathogenesis
that results in a similar decline in lung function in
chronicobstructive pulmonary disease/emphysema [16].
Although the rates of decline in FEV1 are similar in
patients with fixed airflow obstruction caused by asthma
to those with fixed airflow obstruction produced by
emphysema, there are distinct differences between the
two patient populations. Asthmatic subjects with fixed
airway obstruction exhibit more exacerbations, higher
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phil counts. In contrast, sputum neutrophil counts,
comorbidities, and a diminished diffusion capacity are
more characteristic of patients with emphysema [16].
Obviously, the goal of investigations into the remodeling
process in asthma is to gain insights that would
hopefully allow us to prevent or reverse these changes.
Over the past few years, our knowledge in this regard has
increased considerably.
Recent advances
Advances have been made in our understanding of the
ability of presently available treatments to favorably
affect the remodeling process, allowing normal lung
growth in children and preventing the accelerated
decline in lung function in adults. Comparing clinical
studies and other investigations into the mechanism(s)
of the remodeling process, it has become evident that
there may be distinct differences between the pathogenic
mechanisms involved in the remodeling process in
children versus those in adults and, therefore, distinct
differences in their response to treatment.
Several recent clinical studies in children have been
somewhat disappointing in terms of our present day
ability to prevent the remodeling process and thus restore
the normal rate of lung growth [17-19]. Taken as a whole,
these three studies leave the distinct impression that
inhaled corticosteroid therapy, although improving clin-
ical parameters such as symptoms, pulmonary functions,
and quality of life, do not seem to alter the potential for
the diminished lung growth that occurs in childhood
asthma. These studies are in contradistinction to older
studies[20,21],aswellasamorerecent investigation[15],
which demonstrated that the accelerated decline in lung
functionseeninmanyadultasthmaticscanbediminished
by regular administration of inhaled corticosteroids. In
addition, this can beaccompaniedby improvement in the
histopathology associated with the remodeling process in
adults with this condition [20].
Perhaps the distinction between the failure to demon-
strate enhanced lung growth in childhood asthma and
the ability to diminish the accelerated decline in lung
function in adult asthma could be related to differences
in the pathogenesis of these two processes. It has been
traditionally thought that the same remodeling process
that produces an accelerated decline in lung function in
adults also accounts for the diminished lung growth seen
in childhood asthmatics. However, a recent investigation
[22] casts doubt on this assumption. It has long been
known that one of the characteristic features of the
remodeling process in adults is the increased deposition
of ground substances including fibronectin in the
pulmonary parenchyma. It is thought that damage to
the epithelium stimulates fibroblast activation below the
basement membrane, and this results in the manufacture
and deposition of a number of glycoproteins, including
collagen.
In contrast, studies of bronchial epithelial damage in
childhood asthma revealed that children with asthma,
compared to healthy atopic control subjects and healthy
nonatopic control subjects, demonstrate a reduced
capacity of epithelial cells to manufacture fibronectin.
Under normal circumstances, fibronectin assists in the
repair process of bronchial epithelium. The authors
found that childhood asthmatics had a diminished
capacity to produce fibronectin as a result of an innate
abnormality in bronchial epithelial cells. This contrasts
sharply with the overproduction of fibronectin, as
evidenced by deposits of this substance below the
basement membrane, seen in the parenchyma of
remodeled asthmatic airways. Fibronectin can be made
by several different cell types that reside in the airways.
These include fibroblasts, macrophages, and endothelial
and epithelial cells. The precise source of the sub-
basement membrane fibronectin seen in adult asth-
matics is unknown, but presumably the majority is
produced by fibroblasts. Of course, this difference
between adults and children regarding the deposition
of fibronectin may not explain differences noted
between these two groups in their response to inhaled
coticosteroids (see below), but it is at least suggestive of
this possibility.
Implications for clinical practice
The findings noted above imply that in adults with
asthma, early treatment with inhaled corticosteroids,
administered on a daily basis and in sufficient doses,
may have an impact on the remodeling process and
therefore the accelerated decline in pulmonary function
that occurs in a significant proportion of adult
asthmatics.
Unfortunately, available studies to date have not shown
that the use of inhaled corticosteroids favorably affects
Table 1. Factors associated with remodeling in asthma
￿ Bronchial reactivity
￿ Duration of disease
￿ Severity of disease
￿ Presence of atopy
￿ Elevated levels of immunoglobulin E
￿ Eosinophilia
￿ Frequency of severe exacerbations
￿ Increased bronchodilator reversibility (a reflection of airway
hyperreactivity)
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growth. These observations and in vitro studies on
epithelial repair imply that there may be separate
pathogenic mechanisms involved in the remodeling
process in adults and children. Nevertheless, at least at
this point in time in adults, corticosteroids seem to be
the most potent weapon we have against pulmonary
remodeling in asthma.
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